Works matching AU Mangin, Eric

Results: 12

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 962, doi. 10.1002/cpdd.701

By:

Feng, Hwa‐Ping;
Guo, Zifang;
Caro, Luzelena;
Talaty, Jennifer E.;
Mangin, Eric;
Panebianco, Deborah;
Fandozzi, Christine;
Zhu, Yali;
Marshall, William;
Huang, Xiaobi;
Hanley, William D.;
Jumes, Patricia;
Valesky, Robert;
Martinho, Monika;
Butterton, Joan R.;
Iwamoto, Marian;
Yeh, Wendy W.

Publication type:

Article

Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 7, p. 744, doi. 10.1002/cpdd.434

By:

Chen, Xia;
Jiang, Ji;
Hu, Pei;
Zajic, Stefan;
Liu, Wen;
McCrea, Jacqueline;
Liu, Fang;
Witter, Rose;
Mangin, Eric;
Stoch, S. Aubrey

Publication type:

Article

Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.

Published in:

2020

By:

Liu, Kaiyan;
Wu, Depei;
Li, Junmin;
Chen, Hu;
Ning, Hongmei;
Zhao, Ting;
Dai, Haiping;
Chen, Li;
Mangin, Eric;
Winchell, Gregory A.;
Waskin, Hetty;
Jiang, Jun;
Qiu, Yanping;
Zhao, Xu Min

Publication type:

journal article

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.

Published in:

Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 6, p. 1325, doi. 10.1002/cpt.1737

By:

Gao, Wei;
Webber, Andrea L.;
Maxwell, Jill;
Anderson, Melanie;
Caro, Luzelena;
Chung, Chris;
Miltenburg, André M.M.;
Popa, Serghei;
Van Dyck, Kristien;
Wenning, Larissa;
Mangin, Eric;
Fandozzi, Christine;
Railkar, Radha;
Shire, Norah J.;
Fraser, Iain;
Howell, Bonnie;
Talal, Andrew H.;
Stoch, S. Aubrey

Publication type:

Article

No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.

Published in:

European Journal of Clinical Pharmacology, 2017, v. 73, n. 5, p. 593, doi. 10.1007/s00228-017-2216-4

By:

Marshall, William;
Feng, Hwa-Ping;
Caro, Luzelena;
Talaty, Jennifer;
Guo, Zifang;
Huang, Xiaobi;
Panebianco, Deborah;
Ma, Joanne;
Mangin, Eric;
O'Reilly, Terry;
Butterton, Joan;
Yeh, Wendy

Publication type:

Article

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Published in:

PLoS ONE, 2019, v. 14, n. 3, p. 1, doi. 10.1371/journal.pone.0212837

By:

Arrieta, Antonio C.;
Sung, Lillian;
Bradley, John S.;
Zwaan, C. Michel;
Gates, Davis;
Waskin, Hetty;
Carmelitano, Patricia;
Groll, Andreas H.;
Lehrnbecher, Thomas;
Mangin, Eric;
Joshi, Amita;
Kartsonis, Nicholas A.;
Walsh, Thomas J.;
Paschke, Amanda

Publication type:

Article

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia.

Published in:

Open Forum Infectious Diseases, 2019, v. 6, p. S569, doi. 10.1093/ofid/ofz360.1422

By:

Winchell, Gregory A;
Greef, Rik de;
Wrishko, Rebecca E;
Mangin, Eric;
Waskin, Hetty;
Bruno, Christopher

Publication type:

Article

Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.

Published in:

Clinical Drug Investigation, 2019, v. 39, n. 11, p. 1109, doi. 10.1007/s40261-019-00833-1

By:

Li, Haiyan;
Wei, Yudong;
Zhang, Shuang;
Xu, Lin;
Jiang, Jun;
Qiu, Yanping;
Mangin, Eric;
Zhao, Xu Min;
Xie, Shuang

Publication type:

Article

Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Published in:

2019

By:

Wrishko, Rebecca E.;
McCrea, Jacqueline B.;
Yee, Ka Lai;
Liu, Wen;
Panebianco, Deborah;
Mangin, Eric;
Chakravarthy, Manu;
Martinez-Cantarin, Maria P.;
Kraft, Walter K.

Publication type:

Correction Notice

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Published in:

Clinical Drug Investigation, 2019, v. 39, n. 5, p. 441, doi. 10.1007/s40261-019-00764-x

By:

Wrishko, Rebecca E.;
McCrea, Jacqueline B.;
Yee, Ka Lai;
Liu, Wen;
Panebianco, Deborah;
Mangin, Eric;
Chakravarthy, Manu;
Martinez-Cantarin, Maria P.;
Kraft, Walter K.

Publication type:

Article

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Published in:

2015

By:

Sun, Hong;
Yee, Ka Lai;
Gill, Sean;
Liu, Wen;
Li, Xiaodong;
Panebianco, Deborah;
Mangin, Eric;
Morrison, Dennis;
McCrea, Jacqueline;
Wagner, John A.;
Troyer, Matthew D.

Publication type:

journal article

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.

Published in:

2019

By:

Feng, Hwa-Ping;
Guo, Zifang;
Ross, Lisa L;
Fraser, Iain;
Panebianco, Deborah;
Jumes, Patricia;
Fandozzi, Christine;
Caro, Luzelena;
Talaty, Jennifer;
Ma, Joanne;
Mangin, Eric;
Huang, Xiaobi;
Marshall, William L;
Butterton, Joan R;
Iwamoto, Marian;
Yeh, Wendy W

Publication type:

journal article